Vedanta Biosciences Inc v. Seres Therap Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Vedanta Biosciences Inc. (Delaware) and The University of Tokyo (Japan)
  • Defendant: Seres Therapeutics, Inc. (Delaware), Société des Produits Nestlé S.A. (Switzerland), Aimmune Therapeutics, Inc. (Delaware), and Nestle HealthCare Nutrition, Inc. (Delaware)
  • Plaintiff's Counsel: Venable LLP
• Case Identification: 1:24-cv-00957, D. Del., 04/27/2026
• Venue Allegations: Venue is alleged to be proper in the District of Delaware as Defendants Seres Therapeutics, Inc., Aimmune Therapeutics, Inc., and Nestle HealthCare Nutrition, Inc. are Delaware corporations.
• Core Dispute: Plaintiffs allege that Defendants' Vowst® product, a microbiome therapeutic for preventing recurrent Clostridioides difficile infection, infringes seven U.S. patents related to pharmaceutical compositions of spore-forming bacteria and their use in modulating the immune system.
• Technical Context: The lawsuit is situated in the field of microbiome therapeutics, a growing area of medicine focused on using live bacterial compositions to treat diseases by modulating the patient's gut flora and immune response.
• Key Procedural History: The complaint alleges that Defendant Seres Therapeutics challenged the validity of a related European patent (the EPO entry of PCT/JP2011/063302) in an opposition proceeding filed on April 25, 2017, suggesting Defendants had pre-suit knowledge of the patent family.

Case Timeline

Date	Event
2010-06-04	Earliest Priority Date for Asserted Patents
2011-11-14	The University of Tokyo licenses patent rights to Vedanta
2016-09-06	U.S. Patent 9,433,652 issues
2017-04-25	Seres files opposition in European Patent Office to related patent
2017-05-30	U.S. Patent 9,662,381 issues
2017-11-07	U.S. Patent 9,808,519 issues
2020-02-11	U.S. Patent 10,555,978 issues
2021-07-01	Seres and Nestlé enter into License Agreement (approximate date)
2021-08-17	U.S. Patent 11,090,343 issues
2023-04-26	FDA approves Biologics License Application (BLA) for Vowst®
2023-04-27	Vowst® FDA Approval Conference Call held
2023-06-01	Defendants first launch Vowst® (approximate date)
2024-08-01	SPN signs agreement to acquire Vowst® business from Seres (approximate date)
2025-02-04	U.S. Patent 12,214,003 issues
2025-09-09	U.S. Patent 12,409,196 issues
2026-04-27	Plaintiffs' Second Amended Complaint filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent 9,433,652

• Patent Identification: U.S. Patent No. 9,433,652, "Composition for inducing proliferation or accumulation of regulatory T cells," issued September 6, 2016.

The Invention Explained

• Problem Addressed: The patent background describes that while the presence of intestinal bacteria was known to influence the immune system, it was unknown which, if any, specific species of commensal bacteria were responsible for inducing regulatory T cells (Tregs), which are crucial for immune homeostasis Compl. ¶35
• The Patented Solution: The invention identifies that bacteria belonging to the genus Clostridium, when purified and administered to a subject, can induce the proliferation or accumulation of Tregs in the colon Compl. ¶33 This effect can be used to create pharmaceutical compositions from a purified mixture of live, spore-forming bacterial strains (e.g., from Clostridium clusters IV and/or XIVa) to treat infectious or autoimmune diseases '978 Patent, abstract '978 Patent, col. 3:52-57
• Technical Importance: This discovery enabled the development of targeted, composition-based microbiome therapies to modulate the human immune system for treating diseases, moving beyond less-defined methods like fecal transplants Compl. ¶37

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶108
• Essential elements of claim 1 include:
  • A method of treating a human subject having an infectious, autoimmune, or allergic disease.
  • The method comprises administering a pharmaceutical composition.
  • The composition comprises a purified bacterial mixture of at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa.
  • The bacterial strains are spore-forming.
  • The bacterial strains are isolated from a human.

U.S. Patent 9,662,381

• Patent Identification: U.S. Patent No. 9,662,381, "Composition for inducing proliferation or accumulation of regulatory T cells," issued May 30, 2017.

The Invention Explained

• Problem Addressed: As with the '652 patent, the invention addresses the lack of knowledge regarding which specific bacteria could be used to induce Treg proliferation for therapeutic purposes Compl. ¶35
• The Patented Solution: The patent claims a method of treatment using a pharmaceutical composition comprising a "spore-forming fraction of human fecal matter" that is formulated for oral administration Compl. ¶118 This fraction, derived through a process like chloroform treatment or ethanol treatment to enrich for spores, is alleged to induce the proliferation of Tregs and can be used to treat diseases that benefit from immune system enhancement '978 Patent, col. 3:52-57 '978 Patent, col. 4:10-14
• Technical Importance: This method provides a practical approach to creating an oral therapeutic by enriching for the desired spore-forming bacteria directly from a fecal source, rather than requiring isolation and cultivation of individual strains Compl. ¶49

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶118
• Essential elements of claim 1 include:
  • A method of treating a human subject having an infectious, autoimmune, or allergic disease.
  • The method comprises administering a pharmaceutical composition to the subject.
  • The composition comprises a spore-forming fraction of human fecal matter.
  • The composition induces proliferation and/or accumulation of regulatory T cells.
  • The composition is formulated for oral administration.

Multi-Patent Capsules

• U.S. Patent 9,808,519: "Composition for inducing proliferation or accumulation of regulatory T cells," issued November 7, 2017.

  • Technology Synopsis: The '519 patent protects a pharmaceutical composition where the active ingredient "consists of a spore-forming fraction of human fecal matter." The composition is formulated for oral delivery to the intestine and induces the proliferation of Tregs Compl. ¶129 This patent focuses on the composition itself, as distinct from the method claims of the '652 and '381 patents.
  • Asserted Claims: Independent claim 17 is asserted Compl. ¶129
  • Accused Features: The Vowst® product, as a pharmaceutical capsule containing a spore-forming fraction of human fecal matter, is alleged to infringe Compl. ¶131

• U.S. Patent 10,555,978: "Composition for inducing proliferation or accumulation of regulatory T cells," issued February 11, 2020.

  • Technology Synopsis: The '978 patent claims a pharmaceutical composition comprising "one or more purified live bacterial strains" from Clostridium clusters IV or XIVa, isolated from a human, that induces Treg proliferation and is formulated for intestinal delivery. It also covers a method of treating an infectious disease by administering this composition Compl. ¶¶141-142
  • Asserted Claims: Independent claims 1 and 16 are asserted Compl. ¶¶141-142
  • Accused Features: The Vowst® product is alleged to be the claimed composition, and its administration to patients for C. difficile infection is alleged to be the claimed method Compl. ¶¶139-140

• U.S. Patent 11,090,343: "Composition for inducing proliferation or accumulation of regulatory T cells," issued August 17, 2021.

  • Technology Synopsis: Similar to the '978 patent, the '343 patent is directed to a pharmaceutical composition comprising "one or more purified live bacterial strains" from Clostridium clusters IV or XIVa. It adds the express limitation that the strains are "human commensal bacteria" Compl. ¶155 It also claims the method of treating an infectious disease with this composition Compl. ¶156
  • Asserted Claims: Independent claims 1 and 16 are asserted Compl. ¶155 Compl. ¶156
  • Accused Features: The Vowst® product and its use for treating C. difficile infection are the accused instrumentalities Compl. ¶¶153-154

• U.S. Patent 12,214,003: "Composition for inducing proliferation or accumulation of regulatory T cells," issued February 4, 2025.

  • Technology Synopsis: The '003 patent claims a pharmaceutical composition in capsule form comprising a "spore-forming fraction of human fecal matter" that has been "obtained by enriching human fecal matter for a population of spore-forming bacteria" and comprises at least two bacterial strains. The composition is recited as inducing Treg proliferation Compl. ¶168
  • Asserted Claims: Independent claim 1 is asserted Compl. ¶168
  • Accused Features: The Vowst® product, as a pharmaceutical capsule, is alleged to embody the claimed composition Compl. ¶¶167, 170

• U.S. Patent 12,409,196: "Composition for inducing proliferation or accumulation of regulatory T cells," issued September 9, 2025.

  • Technology Synopsis: The '196 patent claims a pharmaceutical composition comprising "six or more live bacterial strains" from Clostridium clusters IV and/or XIVa that induces Treg proliferation. It requires that at least one strain is a human commensal bacterial strain and that the composition is formulated for intestinal delivery Compl. ¶180 It also claims a method of treating disease with this composition Compl. ¶181
  • Asserted Claims: Independent claims 1 and 16 are asserted Compl. ¶180 Compl. ¶181
  • Accused Features: The Vowst® product, alleged to contain six or more such strains, and its use are accused of infringement Compl. ¶¶178-179 Compl. ¶183

III. The Accused Instrumentality

Product Identification

• The accused product is Vowst® (fecal microbiota spores, live-brpk), a drug product developed by Seres Therapeutics and co-commercialized with Nestlé Compl. ¶¶1, 9, 96

Functionality and Market Context

• Vowst® is a pharmaceutical composition in capsule form for oral administration, indicated for the prevention of recurrence of Clostridioides difficile infection (rCDI) in individuals 18 years of age and older following antibacterial treatment for rCDI Compl. ¶¶80-81
• The complaint alleges Vowst® is manufactured from human fecal matter sourced from qualified donors. The manufacturing process involves treating the fecal matter with ethanol to kill non-spore organisms, followed by filtration, resulting in a "bacterial spore suspension" Compl. ¶85 Each capsule is alleged to contain between 1x10⁶ and 3x10⁷ Firmicutes spore colony forming units Compl. ¶87
• A graphic from the Vowst® website, included in the complaint, explains that the product is believed to work by adding "good bacteria" to the gut to restore the microbiome's balance and prevent C. diff from recurring Compl. ¶83 The complaint also references a slide from a Vowst® FDA Approval Conference Call highlighting the co-commercialization relationship between Seres and Nestlé Compl. ¶96

IV. Analysis of Infringement Allegations

'652 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating a human subject having an infectious disease, an autoimmune disease, or an allergic disease,	Vowst® is indicated for the prevention of recurrence of Clostridioides difficile infection, which the complaint frames as treating a human suffering from an infectious disease.	¶81	col. 14:1-5
the method comprising administering a pharmaceutical composition comprising a purified bacterial mixture	Vowst® is administered to patients according to its prescribing information. It is alleged to be a purified bacterial mixture because it is manufactured via ethanol treatment and filtration to remove non-spore organisms and solids.	¶¶82, 85	col. 9:44-48
of at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa to the human subject,	Vowst® is alleged to contain live bacterial strains from the phylum Firmicutes, which includes the genus Clostridium, and are alleged to belong to clusters IV and/or XIVa.	¶¶85, 87-88	col. 12:1-12
wherein the bacterial strains are spore-forming bacteria	Vowst® is a "bacterial spore suspension" containing between 1x10⁶ and 3x10⁷ Firmicutes spore colony forming units per capsule.	¶¶85, 87	col. 12:45-48
and are isolated from a human.	Vowst® is manufactured from human fecal matter sourced from qualified donors.	¶85	col. 12:1-4

'381 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating a human subject having an infectious disease, an autoimmune disease or an allergic disease,	Vowst® is indicated for the prevention of recurrence of C. difficile infection.	¶81	col. 14:1-5
the method comprising administering to the subject a pharmaceutical composition comprising a spore-forming fraction of human fecal matter,	Vowst® is a "bacterial spore suspension" manufactured from human fecal matter, which the complaint equates to a "spore-forming fraction." It is administered to patients.	¶¶82, 85, 87	col. 12:8-14
wherein the composition induces proliferation and/or accumulation of regulatory T cells,	The complaint alleges that Vowst® increases butyrate levels, and that butyrate supports the proliferation of regulatory T-cells.	¶89	col. 3:42-45
and wherein the composition is formulated for oral administration.	Vowst® is provided in capsules for oral administration.	¶82	col. 16:45-48

• Identified Points of Contention:
  • Scope Question ('652 Patent): A central dispute may be the meaning of a "purified bacterial mixture." The complaint alleges Vowst® meets this limitation because it is processed with ethanol and filtered Compl. ¶85 The court will need to determine if this enrichment process for spores from a complex starting material (feces) results in a "purified mixture" as contemplated by the patent, or if "purified" requires a higher degree of isolation, such as combining individually cultured strains.
  • Technical Question ('381 Patent): The infringement theory for the "induces proliferation" limitation rests on a multi-step inference: Vowst® contains bacteria that produce butyrate, and butyrate supports Treg proliferation Compl. ¶89 A key question will be one of causation: does the complaint provide sufficient factual support to show that administering Vowst® itself directly induces Treg proliferation as required by the claim, or is this link too indirect or merely correlational for infringement?

V. Key Claim Terms for Construction

• The Term: "purified bacterial mixture" ('652 Patent, Claim 1)

• Context and Importance: This term is critical for the '652 patent. Vowst® is manufactured from filtered fecal matter, not by combining individually grown strains. The case may turn on whether Vowst®'s composition, created through an enrichment process, qualifies as "purified."

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification describes isolating bacteria from fecal matter using chemical treatments that result in a "combination" of spore-forming bacteria, which may support an interpretation that an enriched fraction is "purified" '978 Patent, col. 3:52-57
  • Evidence for a Narrower Interpretation: The patent also describes creating mixtures from specific, identified strains, which could suggest that "purified" requires starting with isolated components rather than enriching a complex mixture '978 Patent, col. 12:1-12 Practitioners may focus on this term as it appears to be a direct mismatch between the claim language and the alleged manufacturing process of the accused product.

• The Term: "induces proliferation and/or accumulation of regulatory T cells" ('381 Patent, Claim 1)

• Context and Importance: This functional limitation is the mechanism of action claimed by the patent. The infringement allegation relies on an indirect mechanism (butyrate production). The construction of "induces" will determine how direct the causal link between the composition and the Treg effect must be.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification focuses on the end result-the accumulation of Tregs-and describes bacteria "belonging to the genus Clostridium" as the active agent, which could allow for various biological pathways initiated by those bacteria '978 Patent, col. 3:42-45 '978 Patent, abstract
  • Evidence for a Narrower Interpretation: The patent repeatedly links the administration of the composition to the Treg effect, which could be argued to imply a more direct, proximate cause rather than a downstream, multi-step biological cascade '978 Patent, col. 3:52-57

VI. Other Allegations

• Indirect Infringement: The complaint alleges Defendants induce infringement by healthcare professionals and patients who use Vowst® according to its FDA-approved label and prescribing information Compl. ¶¶105-106, 110 It is also alleged that Seres induced Nestlé to infringe through their co-commercialization agreement Compl. ¶98
• Willful Infringement: Willfulness is alleged based on pre-suit knowledge. The complaint points to Seres's 2023 10-K, which acknowledges awareness of "third-party patent families...that could be construed to cover Vowst®," and its 2017 opposition to a related European patent, which belongs to the same family as the Asserted Patents Compl. ¶101

VII. Analyst's Conclusion: Key Questions for the Case

1. A central issue will be one of definitional scope: does the manufacturing of Vowst®-which involves treating fecal matter with ethanol to enrich for spores-result in a "purified bacterial mixture" as required by the '652 patent, or does "purified" require a more rigorous process of isolation and recombination not present here?
2. A key evidentiary question will be one of functional causation: does the complaint provide sufficient evidence that Vowst® directly "induces proliferation and/or accumulation of regulatory T cells," as required by the '381 patent and others, or is the alleged link via an intermediate metabolite (butyrate) too indirect to support a finding of literal infringement?
3. A third question relates to prior art and validity: given the defendant's alleged prior opposition to a related European patent, the case may heavily feature arguments about the validity of the asserted claims in light of prior art that was before the European Patent Office, potentially raising significant questions about the novelty and non-obviousness of the inventions.